U.S. Markets open in 5 hrs 19 mins

Bridge Bancorp, Inc. (BDGE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.01+0.48 (+2.90%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close16.53
Bid0.00 x 800
Ask0.00 x 800
Day's Range16.64 - 17.54
52 Week Range16.51 - 34.25
Avg. Volume118,801
Market Cap335.856M
Beta (5Y Monthly)1.07
PE Ratio (TTM)7.06
EPS (TTM)2.41
Earnings DateJul 28, 2020
Forward Dividend & Yield0.96 (5.81%)
Ex-Dividend DateJul 17, 2020
1y Target Est22.85
  • GlobeNewswire

    Moore Kuehn Encourages BDGE, CBMG, CGIX, and BMCH Investors to Contact Law Firm

    NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: * Bridge Bancorp, Inc. (NASDAQ GS: BDGE) A registration statement was recently filed with the SEC regarding Bridge Bancorp’s merger with Dime Community Bancshares. Upon completion of the merger, shareholders of Dime will receive 0.6480 shares of Bridge Bancorp for every share owned.   The investigation concerns whether Bridge’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price. * Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) Cellular Biomedicine has agreed to be acquired by consortium led by the company’s CEO Bizuo Liu. Under the proposed transaction, shareholders of Cellular Biomedicine will receive $19.75 for every share owned. * Cancer Genetics, Inc. (NASDAQ: CGIX) Cancer Genetics has agreed to merge with StemoniX. Under the proposed transaction, Cancer Genetics will issue shares of common stock to the owners of StemoniX, with current holders of Cancer Genetics common stock controlling only 22% of the combined company. * BMC Stock Holdings, Inc. (NASDAQ: BMCH) BMC has signed an agreement to merge with Builders FirstSource. Under the proposed transaction, shareholders of BMC will receive1.3125 shares of Builders FirstSource for every share owned.Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process.Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245. The consultation and case are free with no obligation to you. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.Moore Kuehn is a 5-star New York City-based law firm with attorneys representing investors and consumers in class action litigation involving securities law violations, financial fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please go to http://www.moorekuehn.com/practice/new-york-securities-litigation/.Attorney advertising. Prior results do not guarantee similar outcomes.Contacts: Moore Kuehn, PLLC Justin Kuehn, Esq. 30 Wall Street, 8th Floor New York, New York 10005 jkuehn@moorekuehn.com (212) 709-8245

  • SHAREHOLDER ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm – BYFC, BMCH, MOXC, BDGE

    SHAREHOLDER ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm – BYFC, BMCH, MOXC, BDGE

    NEW YORK, NY / ACCESSWIRE / August 29, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate:Broadway Financial Corporation (NASDAQ:BYFC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with CFBanc Corporation.